News and Announcements
Novapep’s Pioneering Approach to Treating Inflammatory Bowel Diseases
- Published October 15, 2024 7:42AM UTC
- Publisher Maan Perez
- Categories Executive Interviews
Join Jay Hennock, CEO of Novapep, as he unveils the company’s mission to address unmet medical needs through peptide-based therapies.
Novapep, an Australian/US biotech, has developed a patented peptide structure called biparediteTM as an oral inflammatory bowel disease therapy, which will be a cost effective first-in-class drug. Biparetide has been shown in animals to be as effective as expensive, injectable biologic drugs (a US$20 billion market) and superior to corticosteroids, but with minimal expected side effects.
This video provides a compelling overview of their research and development efforts, focusing on inflammatory skin disorders, bowel disease, and sepsis, and their impact on global health.
Executive Interviews
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
The Great Re-Allocation: Why AI is Forcing Smart Money From Software to Hard Science
Smart money is rapidly shifting its investment focus from commoditized software to hard science and deep tech, as AI dissolves traditional software moats. Discover the dual pressure on investors and the pivot to businesses with durable, real-world defensive barriers.
AI is The Cheapest, Highest-Leverage Investment You Will Ever Make
AI tools offer a 10x productivity increase for a minimal monthly cost, making them the highest-ROI investment in business today. However, this massive potential remains dormant. The real opportunity is not in owning the tools, but in having the strategic playbook to deploy them organization-wide and build a defensible competitive advantage.
Backed By Leading Investment Groups and Family Offices
